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Background: Soy protein in combination with soy isoflavones might reduce the serum concentration of inflam-
matory mediators. In this study, we attempted to summarize the effect of soy protein combined with soy iso-
flavones on circulating E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion 
molecule-1 (VCAM-1) in adults. 
Methods: Clinicaltrials.gov, Web of Science, Cochrane Library, PubMed, and Scopus were searched for English 
articles with no time limit regarding publication up to December 2020. Thereafter, the mean changes from 
baseline and their standard deviations (SDs) for both intervention and comparison groups were used to calculate 
the effect size. We used DerSimonian and Laird random-effects model if the heterogeneity test was statistically 
significant. Cochran’s Q test and I-squared statistic were also used to calculate the statistical heterogeneity of the 
intervention effects. 
Results: Eight articles were found as eligible for this study. The treatment duration was between 6 and 24 weeks. 
Soy isoflavones dose was in a range of 30–112 mg/day and soy protein dose was in a range of 11.25–52 g/day. 
Overall, taking soy protein supplements containing soy isoflavones was not associated with changes in cell 
adhesion molecules, E-selectin, ICAM-1, or VCAM-1 (WMD = 0.65, 95 % CI: -2.58, 3.89; p = 0.692; WMD = 2.68, 
95 % CI: -0.98, 6.34; p = 0.151; WMD = 2.66, 95 % CI: -6.28, 11.61; p = 0.559, respectively). 
Conclusion: The combination of soy protein and soy isoflavones was not significantly associated with changes in 
levels of E-selectin, ICAM-1, and VCAM-1. However, we need more studies with a large sample size and more 
participants with different age categories in this regard.   
1. Introduction 
Chronic inflammation known as the most important risk factor for 
cardiovascular diseases (CVDs) 1 which is responsible for nearly 30 % of 
all deaths in low-and middle-income countries. 2–4 Inflammation can 
modify both the morphology and function of endothelial cells, persis-
tently activate endothelial cells, and contribute into endothelial 
dysfunction. 5 Furthermore, cytokine enhancement causes the expres-
sion of glycoproteins gene of endothelial cells such as E-selectin, inter-
cellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion 
molecule-1 (VCAM-1). 6 Under normal conditions, cell adhesion mole-
cules (CAMs) are associated with cell-matrix adhesion and cell-cell 
communication, so these molecules can control the locomotion and 
migration of leukocytes across the endothelium. However, under some 
abnormal conditions like hypertension, the increased CAMs level can 
result in accelerating the progression of atherosclerosis. 7 
The concentration of inflammatory mediators could be affected by 
various factors such as diet and specific nutrients. 8,9 The diet’s effects 
on endothelial function and serum levels of inflammatory mediators 
have been examined in some previous studies. 10,11 
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Since soy peptides may have anti-inflammatory effects, 12 some ar-
ticles have investigated the effects resulted from the soy consumption. 
13,14 According to the results of these studies, the reduction in animal 
protein intake and the increase in soy protein intake might consequently 
decrease the serum concentration of CAMs and other inflammatory 
mediators. 13,14 Soy contains a high amount of L-arginine and previous 
experimental studies have indicated that L-arginine supplementation 
could decrease the expression of inflammatory cytokines. 15 Moreover, 
in vitro studies have proposed that L-arginine as nitrite oxide (NO) do-
nors can prevent the expression of pro-inflammatory genes by the in-
hibition of nuclear factor kappa B (NFҡB). 16,17 
Besides protein, soy also contains phytoestrogens, which are indi-
vidually associated with the reduced levels of inflammatory mediators 
and improved endothelial function. Soy isoflavones are bioactive mol-
ecules with a similar structure to 17b-estradiol. 18 Soy isoflavones have 
been hypothesized to have the ability of protection against coronary 
vascular disease by increasing nitric oxide and reducing CAMs concen-
trations. 19–27 
Moreover, scientists have proposed that soy isoflavones can modu-
late the expression of inflammatory genes by inhibiting the c-Jun N- 
terminal kinase (JNK) pathway as well as regulating the pathways 
involved in both the peroxisome proliferator-activated receptor alpha 
(PPAR-α) and –γ activation. 28,29 
However, the results of previous randomized clinical trials (RCTs) 
are contradictory in this regard. Some studies indicated the beneficial 
effects of soy products on concentrations of CAMs, while some other 
studies reported no effect. Therefore, since there was no study assessing 
the effect of soy protein containing isoflavones on E-selectin, ICAM-1, 
and VCAM-1 on adults, in the current study, we attempted to conduct 
a systematic review and meta-analysis to summarize the effect of soy 
protein containing isoflavones on CAMs among adults. 
2. Materials and methods 
We used PRISMA-2020 (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) checklist for all steps of the present sys-
tematic review and meta-analysis (Supplementary appendix). 
Of note, a systematic search was performed using Clinicaltrials.gov, 
Web of Science, Cochrane Library, PubMed, and Scopus up to December 
2020. Accordingly, the query syntax for searching these databases is 
reported in Table 1, in the supplementary appendix. In order to find 
more eligible articles, the reference list of all the selected articles was 
manually searched, as well. To design the search strategy, we used 
Boolean operators (AND & OR). In addition, to search the exact terms, 
we used quotation marks, and to search all words derived from one 
keyword, asterisks were used. It is noteworthy that if the database was 
searched based on the keywords of E-selectin, ICAM1 and VCAM1, few 
articles would be missed. To this end, some key words related to the 
most important inflammatory mediators were used. All the found arti-
cles were then imported to EndNote software (reference manager soft-
ware, version X6) and two reviewers (MH and AGh) separately read 
their titles and abstracts. Any discrepancy at this stage was resolved by 
the group discussions. We did not limit our search to study design and 
publication time. The protocol of this study was registered with PROS-
PERO (No. CRD42020166053). 
2.1. Inclusion criteria 
Two reviewers (MH and AGh) decided on including or excluding 
articles from the current systematic review and meta-analysis in terms of 
the following criteria. The inclusion criteria for this systematic review 
and meta-analysis were the PICOS (Patient/Population, Intervention, 
Comparison, Outcome, Study types) framework as follows: I) popula-
tion: Healthy and unhealthy participants; II) intervention: Natural or 
commercial soy products containing both protein and isoflavones; III) 
comparison: Control group; IV) outcome: Reporting the baseline and 
follow-up levels of the serum concentrations of E-selectin, ICAM-1, and 
VCAM-1 in the intervention group or the comparison group; and V) 
study design: Parallel or cross-over RCT. 
2.2. Exclusion criteria 
The articles that met the following criteria were not included in our 
systematic review and meta-analysis: 1) articles reporting data in fig-
ures; 2) those that had a treatment duration less than one week; 3) those 
articles with no comparison group; 4) those articles that did not report 
the dose of soy protein or isoflavones or reporting no information to 
estimate them; 5) those in which participants took other food supple-
ments besides soy products; 6) those articles in which the participants 
only took soy isoflavones or soy protein; 7) the articles reporting no 
information on the serum concentration of the desired outcome at 
baseline or after intervention and gave no information to compute it; 
and 8) non-English articles. 
2.3. Data extraction 
In this study, two reviewers (MH and AGh) independently performed 
the study’s screening, methodological quality assessment, validation, 
and selection. Afterward, the following data were extracted from the 
selected studies: the information on study design, publication year, the 
country in which the study was conducted, the first-author’s name, total 
sample size, sample sizes of both intervention and comparison groups, 
anthropometric and demographic variables (including sex, age, Body 
Mass Index (BMI)), health status, the dose of soy protein and isoflavones, 
kind of placebo, intervention duration, and the serum concentrations of 
E-selectin, ICAM-1, and VCAM-1 before and after performing the 
intervention. At this stage, any discrepancy was resolved through 
consulting until reaching an agreement. All the units regarding E- 
selectin, ICAM-1, and VCAM-1 were then converted into a same unit 
(ng/mL). As well, the studies with more than one comparison or inter-
vention group were considered as separated articles. Of note, an email 
was sent to the corresponding author to clarify any unclear information, 
if needed. 
2.4. Quality assessment 
To assess the quality of the included RCTs, Cochrane Collaboration’s 
tool was used by the two independent reviewers (MH and AGH). 30 The 
following items were then used to assess the risk of bias in this study: I) 
conducting adequate sequence generation; II) conducting allocation 
concealment; III) blinding both participants and personnel; IV) blinding 
the outcome assessment; V) incomplete report of outcome data; and VI) 
selective reporting. Each item was then judged as “low risk of bias”, 
“high risk of bias”, or “unclear risk of bias” by the reviewers; therefore, 
each one of the included studies in this review was scored as “good” if it 
met at least three items of low risk of bias, “fair” if it met at least two 
items of low risk of bias, and “weak” if it met less than two items of low 
risk of bias. 
2.5. Data synthesis and statistical analysis 
At this stage, mean differences (MDs) and their standard deviations 
(SDs), which were used to conduct this meta-analysis, were calculated 
by subtracting baseline values from the post-intervention values in the 
included articles. 
The effect size of the intervention and comparison groups was 
calculated by the mean change from baseline and their SD was estimated 
in terms of the Cochrane Handbook. In those studies that reported 
standard error (SE), SD was calculated by multiplying SE in the square 
root of the sample size. Based on the Hozo’s method, the mean was 
estimated using the median or range reported in the included articles. 31 
Thereafter, both Cochran’s Q test and I-squared statistic were used to 
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Table 1 
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0.5 cups/day soy nuts 
(containing 25 g of soy 
protein and 101 mg of 
aglycone soy 
isoflavones) 
Non soy protein 8 
ICAM-1, 
VCAM-1 
There were no 
significant changes in 
between groups 
analysis regarding 











± 6.5 Randomized, 
controlled, cross- 
over trial 
0.5 cups/day soy nuts 
(containing 25 g of soy 
protein and 101 mg of 
aglycone soy 
isoflavones) 











± 4.6 Israel N = 11 
2.1 Postmenopausal 





over clinical trial 
30 g/day soy nut 
(containing 11.25 g/ 
day protein with 84 
mg/day isoflavones) 







ICAM-1 and VCAM-1 







N = 42 
Iran 
2.2 Postmenopausal 
women with the 
metabolic syndrome 
Age: 57 ±
1.94 Randomized cross- 
over clinical trial 
30 g/day soy protein 
diet (containing 15 g/ 
day protein with 102 
mg/day isoflavones) 





and VCAM-1 did not 
significantly change 
Azadbakht, 
L 37 2007 BMI: 28 ±
1.29 Iran N = 42 
3.1 Prehypertensive/ 
Stage 1 Hypertensive 
Individuals 
Age: 29 
(24− 43) Randomized 
clinical trial 
Soy beverage prepared 
from soy protein isolate 
(containing 18 g soy 








ICAM-1, VCAM-1, and 






29.0) N = 44 USA 
3.2 Prehypertensive/ 
Stage 1 Hypertensive 
Individuals 
Age: 29 
(24− 43)* Randomized 
clinical trial 
Soy beverage prepared 
from whole soy bean 
(18 g soy protein and 






ICAM-1, VCAM-1, and 










± 6.0 Randomized cross- 
over 
26 ± 5 g protein 
containing 44 ± 8 mg 
isoflavones per day 




ICAM-1, VCAM-1, and 
E-selectin did not 
change significantly 
Greany, K. A 
19 USA BMI: 25.0 








15 g soy protein and 







ICAM-1, VCAM-1, and 
E-selectin did not 
change significantly 
BMI: N/M Liu, Z. M 
20 
2013 Soy isoflavones N = 33 
China 









15 g soy protein and 










did not change 
significantly 
Liu, Z. M20 
2013 BMI: N/M 
Soy isoflavones 










52 g/day of soy protein 
containing 63 mg of 
genistein, 43 mg of 
daidzein and 6 mg of 
glycitein, altogether 
112 mg of isoflavones 




ICAM-1 and VCAM-1 





± 5.3 Finland 





















ICAM-1, VCAM-1, and 
E-selectin did not 
change significantly. 
Rebholz, C. 
M39 2013 N = 102 BMI:29.5 ±
3.8 
F = 34 
























M39 2013 BMI:29.5 ±
3.8 
N = 102 
F = 34 
USA M = 68 





25 g/day soy protein 
and 90 mg/day soy 
isoflavones 
Milk protein 6 VCAM-1 
VCAM-1 did not 
significantly change 
West, S. G40 
2005 N = 14 BMI: 25.89 









25 g/day soy protein 
and 90 mg/day soy 
isoflavones 
Milk protein 6 VCAM-1 VCAM-1 did not 
significantly change 
West, S. G40 
2005 BMI: 26.17 





± 1.54 Randomized, 
double-blind, 
cross-over trial 
25 g/day soy protein 
and 90 mg/day soy 
isoflavones 
Milk protein 6 VCAM-1 
VCAM-1 did not 
significantly change 
West, S. G40 
2005 BMI: 26.80 
± 0.93 N = 12 USA 
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calculate the statistical heterogeneity of the intervention effects. If the 
heterogeneity test’s result was statistically significant, we would then 
estimate the summary of the overall effect and its heterogeneity using 
DerSimonian and Laird random-effects model. 32 A p-value≤0.10 for 
Cochran’s Q test and the I-squared statistic value ≥50 % indicated a 
statistically significant heterogeneity. 33 
The sources of heterogeneity were found by conducting subgroup 
analysis, including age; sex; intervention duration; study design; BMI; 
the doses of soy protein and soy isoflavones; health status; sample size; 
geographical region; quality assessment; publication year; and baseline 
levels of E-selectin, ICAM-1, and VCAM-1.Subsequently, we evaluated 
the publication bias using Begg’s funnel plot, Begg’s rank correlation, 
and Eggar’s weighted regression test. 34,35 Sensitivity analysis was also 
used to evaluate the effect of each study on the overall effect size. The 
statistical significance level was set at 0.05 and 95 % confidence interval 
was presented for all the calculated effect sizes. All the statistical ana-
lyses in this study were performed using STATA version 15 (Stata Corp, 
College Station, TX, USA). 
3. Results 
3.1. Systematic review findings 
By searching all the above-mentioned databases, 4387 articles were 
retrieved. After identifying and removing duplicate articles, 2955 arti-
cles remained for reading the titles and the abstracts. Thereafter, by 
reading the titles and the abstracts, 2833 articles were excluded. Finally, 
122 articles remained for assessing their full text. Next, based on the 
inclusion and exclusion criteria, 114 studies were excluded due to the 
following reasons: three articles were excluded due to the administra-
tion of soy intake mixed with other dietary regimens; two studies were 
removed because they had no comparison groups; 106 studies were 
excluded because the serum concentrations of E-selectin, ICAM-1, and 
VCAM-1 were not measured in them; one study was removed because 
the participants only took soy protein; and two studies were removed 
because the participants only took soy isoflavones. (Fig. 1). Therefore, 
this systematic review and meta-analysis included eight studies 
13,19,20,36–40 (Table 1). 
According to the results of our systematic review, five included 
studies assessed the effect of soy protein combined with soy isoflavones 
on the serum concentration of E-selectin. 13,19,20,37,39 Three studies were 
conducted on postmenopausal women 37,19,20 and two studies were 
performed on both men and women. 13,39 Notably, the range of soy 
protein dose was from 11.25 g/day to 40 g/day and the range of soy 
isoflavones administration was from 30 mg/day to 102 mg/day. As well, 
four studies had more than one intervention group; therefore, we 
considered them as the separated articles 37,13,20,39 (Table 1). 
The effect of soy protein containing soy isoflavones on ICAM-1 was 
assessed in seven studies included in this review. 13,19,20,36–39 Five 
studies were conducted on postmenopausal women 37,19,20,36,38 and two 
studies were performed on both male and female cases. 13,39 The range 
of soy protein dose was between 11.25 g/day and 52 g/day and the 
range of soy isoflavones administration was between 30 mg/day and 
112 mg/day. Of note, five studies had more than one intervention group; 
therefore, we considered them as the separated articles 
37,13,20,39,36(Table 1). 
In regard to VCAM-1, eight studies assessed the effect of soy protein 
containing soy isoflavones on the serum concentration of VCAM-1. 
Abbreviation: ICAM-1: Intercellular Adhesion Molecule, VCAM-1: Vascular cell adhesion protein; BMI: Body Mass Index; N/M: Not mention; RCT: Randomized clinical 
trial. 
* Mean (95 % confidence interval). 
Fig. 1. Flowchart of study selection process.  
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13,19,20,36–40 One article had more than one comparison group, 39 two 
articles had more than one intervention group, 13,37 and two other ar-
ticles were conducted on separate participants. 36,40 Therefore, all these 
studies were reported as the separated studies. In three articles, the 
participants received the combination of soy isoflavones and soy protein 
by natural soy products. 36,38,39 Moreover, soy supplements or com-
mercial soy products were administered in four studies13,19,20,40 and 
both supplements and natural soy products were used only in one study. 
37 Their treatment duration ranged from 6 to 24 weeks. Notably, soy 
isoflavones dose was in a range of 30–112 mg/day and soy protein dose 
was in a range of 11.25–52 g/day (Table 1). 
3.2. Risk of bias assessment 
Out of the eight RCTs included in this study, three RCTs were scored 
as “good” 13,20,39 and five RCTs were scored as “fair”, .19,36–3840 In 
addition, Four RCTs had a high risk of bias according to blinding the 
participants, personnel, 19,36–38 or outcome assessors. 13,20,38,40 In terms 
of the allocation concealment, one study had a high risk of bias. 13 The 
two studies performed by Liu, Z. M. et al. 20 and West, S. G. et al. 40 had 
bias associated with the incomplete outcome data and selective report-
ing, respectively. More detailed information on the quality assessment of 
the included RCTs are presented in Table 2. 
3.3. Meta-analysis findings 
In total, five RCTs with nine effect sizes were evaluated to indicate 
the effect of soy protein containing soy isoflavones on the serum con-
centrations of E-selectin (Fig. 2). As a result, the overall effect revealed a 
non-significant effect on the serum concentrations of E-selectin after 
taking soy protein in combination with soy isoflavones compared with 
the comparison group (WMD = 0.65, 95 % CI: -2.58, 3.89; p = 0.692). 
Also, a substantial heterogeneity was found among the included studies 
(Cochrane’s Q test, p < 0.001; I2 = 91.4 %). 
The effect of soy protein containing soy isoflavones on ICAM-1 was 
assessed in seven studies with twelve effect sizes. According to the re-
sults of this meta-analysis, taking soy protein in combination with iso-
flavones had no significant effect on the serum concentrations of ICAM-1 
compared with the comparison group (WMD = 2.68, 95 % CI: -0.98, 
6.34; p = 0.151) (Fig. 3). Also, a significant heterogeneity was found 
among the included studies (p < 0.001; I2 = 67.6 %). 
Concerning the effect of soy protein containing soy isoflavones on 
VCAM-1, in total, eight RCTs with 15 effect sizes were included in this 
meta-analysis (Fig. 4). According to the results of the current meta- 
analysis, this combination was not significantly associated with reduc-
tion in serum concentration of VCAM-1 compared to the comparison 
group (WMD = 2.66, 95 % CI: -6.28, 11.61; p = 0.559). Of note, there 
was a significant heterogeneity among the included studies (p < 0.001; 
I2 = 71.3 %). 
By performing the sensitivity analysis, it was revealed that excluding 
each trial from the overall analysis did not cause a significant change in 
the overall effect size of soy protein combined with soy isoflavones on 
the concentrations of E-selectin, ICAM-1, and VCAM-1. Although the 
funnel plots for E-selectin, ICAM-1, and VCAM-1 were not visually 
symmetric, Begg’s rank correlation and Egger’s weighted regression test 
indicated no evidence of publication bias in this regard (E-selectin: 
Begg’s: P = 0.536 and Egger’s test: P = 0.471; ICAM-1: Begg’s: P = 0.268 
and Egger’s test: P = 0.162; VCAM-1: Begg’s: P = 0.381 and Egger’s test: 
P = 0.613) (Fig. 5). 
3.4. Subgroup analysis findings 
The results of the subgroup analysis revealed that this combination 
reduced the concentration of E-selectin with a non-significant hetero-
geneity when sample size was >84 (WMD= -2.88, 95 % CI: -4.62, -1.14; 
p = 0.001; I2 =40.6 %). Moreover, the heterogeneity was non-significant 
among those studies performed in the Americas region (p = 0.080; I2 =
71.2 %) (Table 3). The concentration of ICAM-1 also reduced in none of 
the subgroup analyses (Table 4). Heterogeneity was not significant 
among the studies with the intervention duration >56 days (p = 0.297; 
I2 = 8.00 %) as well as those studies with healthy participants (p =
0.243; I2 = 29.40 %) (Table 4). Soy protein containing soy isoflavones 
decreased the serum concentration of VCAM-1 when participants’ ages 
were ≤55 years old and the heterogeneity was not significant (WMD=- 
18.74, 95 % CI: -32.82, -4.66; p = 0.009; I2 = 24.2) (Table 5). According 
to the results of the subgroup analysis, the heterogeneity was not sig-
nificant among the studies conducted on participants with BMI > 27 (p 
= 0.201; I2 = 29.8 %), the studies conducted on both male and female 
sex (p = 0.378; I2 = 2.9 %), and the studies in the Americas region (p =
0.311; I2 = 15.2 %). 
4. Discussion 
To the best of our knowledge, this is the first systematic review and 
meta-analysis performed to assess the effect of soy protein containing 
isoflavones on the serum CAMs. According to the results of our meta- 
analysis, it was shown that the combination of soy protein and soy 
isoflavones was not significantly associated with changes in the serum 
concentrations of E-selectin, ICAM-1, and VCAM-1. However, the results 
of the subgroup analysis revealed that the serum concentrations of E- 
selectin and VCAM-1 significantly decreased in the studies with a sample 
size >84 for E-selectin, and in the studies conducted on participants 
aged ≤55 years old for VCAM-1. 
The results of a previous meta-analysis on 36 RCTs in 2018 revealed 
that soy products have no beneficial effects on the concentration of CRP 
in the blood. However, they suggested that using natural soy products 
could decrease plasma CRP more than using commercial soy products. 41 
Nevertheless, finding no significant alteration in the serum levels of 
CAMs in this study might be due to the studied population of the 
included studies in the meta-analysis and their ability to produce equol. 
Accordingly, equol is known as one of the most important soy iso-
flavones and is produced from daidzein. 42 The antioxidant activity of 
equol was found to be stronger than other soy isoflavones and scientists 
have proposed that anti-inflammatory activities of soy isoflavones are 
Table 2 
Quality of bias assessment of the included studies according to the Cochrane guidelines.  






Blinding of participants 
and personnel 








Acharjee, 2015 U U H U L L Fair 
Azadbakht, 2007 U U H U L L Fair 
Dettmer, 2012 U H L H L L Good 
Greany, 2008 U U H U L L Fair 
Liu, 2013 L L L H H U Good 
Rebholz, 2013 L U L L U L Good 
Törmälä, 2008 U U H H L L Fair 
West, 2005 L U L H U H Fair 
L, low risk of bias; H, high risk of bias; U, unclear risk of bias. 
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related to some antioxidant properties. 43 In this study, we suggest that 
the non-significant effect of the combination containing soy protein and 
soy isoflavones might possibly be due to the participants’ disabilities to 
produce equol. Of 15 datasets investigated in this meta-analysis, eight 
datasets were conducted in Western countries and no dataset was done 
by Japanese or Korean researchers. In western countries, it was reported 
that less than 30 % of the adults can produce equol, but in Asia, and 
particularly in Japan and Korea, at least 50 % of adults are equol pro-
ducers. 44 Unfortunately, most of the included articles in this 
meta-analysis reported no information on the equol production. 
According to the results of the subgroup analysis, it was indicated 
that the studies with a larger sample size could more reduce the serum 
concentration of E-selectin. It might be possible that the small sample 
size in some of these RCTs caused an insufficient statistical power to find 
any significant difference. 
In the two studies conducted on participants with metabolic syn-
drome 37 and hypertension, 39 the serum levels of E-selectin significantly 
decreased and in another study performed on participants with meta-
bolic syndrome, the serum concentration of ICAM-1 showed a 
significantly decrease. 36 Therefore, the absence of an intervention effect 
may be associated with participants’ health status. In this study, most of 
the included articles were conducted on healthy participants with low 
levels of inflammation, so there may be less room for the improvement 
resulted from taking soy protein combined with soy isoflavones. 
In this meta-analysis, a significant heterogeneity was detected in the 
included studies and even in all the subgroup analyses. We suggested 
that the probable reasons for this heterogeneity might be various sources 
of soy protein and soy isoflavones among the included studies, and 
selecting participants from different countries with different abilities to 
produce equol, different life style, and different health statuses. 
The findings also showed various limitations to the research 
engagement. Firstly, a few numbers of studies for all outcomes, espe-
cially in the subgroup analysis, were included in this study. Therefore, 
the results obtained in the present study could be biased by sample size. 
Secondly, a significant heterogeneity was observed in these included 
articles and even in all the subgroup analyses. Thirdly, since most of the 
included articles provided no information regarding equol production, 
we did not assess whether equol production is able to change the overall 
Fig. 2. Forest plot of the effect of soy protein plus soy isoflavones consumption on serum E-selectin concentrations.  
Fig. 3. Forest plot of the effect of soy protein plus soy isoflavones consumption on serum ICAM-1 concentrations.  
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results of meta-analysis. Next, a few numbers of subjects were involved 
in most of these articles. As another limitation, the intervention duration 
in most articles was short (8 weeks), and only one study followed par-
ticipants for 24 weeks. Finally, most of the RCTs were conducted in the 
Americas region; therefore, the effect of soy protein combined with soy 
isoflavones among Eastern populations remains questionable yet. 
Our study also had several strengths. We did not limit our search to a 
specific publication time. We removed the RCTs in which the subjects 
consumed other nutrients besides soy protein and soy isoflavones in the 
intervention group; therefore, their confounding effects were excluded 
as well. Moreover, our meta-analysis is the first article that examined the 
effect of the combination of soy protein combined with soy isoflavones 
on the CAMs. Finally, we indicated the effects of soy protein dose; soy 
isoflavones dose; BMI; age; sex; geographical region; sample size; trial 
design; health status; intervention duration; publication year; baseline 
levels of E-selectin, ICAM-1, and VCAM-1; and quality assessment on the 
Fig. 4. Forest plot of the effect of soy protein plus soy isoflavones consumption on serum VCAM-1 concentrations.  
Fig. 5. Funnel plots for the publication bias. A: Studies of the effects of soy protein plus soy isoflavones consumption on serum E-selectin concentrations. B: Studies of 
the effects of soy protein plus soy isoflavones consumption on serum ICAM-1 concentrations. C: Studies of the effects of soy protein plus soy isoflavones consumption 
on serum VCAM-1 concentrations. 
M. Hariri et al.                                                                                                                                                                                                                                  
Complementary Therapies in Medicine 61 (2021) 102764
8
Table 3 
Subgroup analyses for studies evaluating the effect of soy protein plus soy isoflavones on serum E-selectin.   
Subgroup No. of trial Change in E-selectin (95 % CI) P-value I2 (%) Pheterogeneity 
Total – 9 0.65 (-2.58, 3.89) 0.692 91.4 <0.001 
Soy isoflavones dose ≤89.5 mg/d 5 − 2.22 (-4.45, 0.01) 0.051 61.5 0.034 
>89.5 mg/d 4 4.21 (-3.10, 11.53) 0.259 95.06 <0.001 
Soy protein dose 
≤18 g/d 6 2.63 (-2.23, 7.49) 0.289 94.5 <0.001 
>18 g/d 3 − 1.89 (-4.23, 0.46) 0.114 39.0 <0.001 
Design 
Parallel 4 1.70 (-3.77, 7.17) 0.542 82.3 0.001 
Cross-over 5 0.09 (-4.76, 4.94) 0.971 94.7 <0.001 
Intervention duration ≤56 day 7 2.10 (-2.68, 6.87) 0.390 93.1 <0.001 
>56 day 2 − 1.71 (-5.52, 2.10) 0.379 82.6 0.017 
Baseline E-selectin ≤38 ng/mL 4 − 0.27 (-4.12, 3.58) 0.891 78.1 0.003 
>38 ng/mL 5 1.30 (-4.26, 6.86) 0.647 95 <0.001 
Health status 
Healthy 1 0.40 (-2.34, 3.14) 0.775 – – 
At risk/disease 8 0.80 (-2.86, 4.46) 92.3 0.668 <0.001 
Sample size 
≤84 6 4.01 (-1.92, 9.93) 0.185 94.1 <0.001 
>84 3 − 2.88 (-4.62, -1.14) 0.001 40.6 0.186 
Geographical Region 
Americas 5 0.32 (-3.85, 4.49) 0.881 71.2 0.080 
Europe – – – – – 
Asia 4 0.50 (-4.45, 5.46) 0.842 96.2 <0.001 
Sex 
Female 5 0.35 (-3.95, 4.66) 0.873 95 <0.001 
Male – – – – – 
Both 4 1.41 (-4.35, 7.18) 0.631 77.8 0.004 
Age 
≤49 years 4 1.41 (-4.35, 7.18) 0.631 77.8 0.004 
>49 year 3 − 1.42(-4.30, 1.46) 0.333 69.9 0.036 
Unknown 2 2.74 (-10.19, 15.68) 0.678 98.6 <0.001 
BMI 
≤27.5 5 0.69 (-3.42, 4.8) 0.743 77.3 0.001 
>27.5 4 0.18 (-5.52, 5.89) 0.949 96 <0.001 
Unknown 5 − 0.01 (-0.18, 0.17) 0.949 79.0 0.001 
Quality assessment 
Good 6 − 0.98 (-3.81, 1.84) 0.495 74.4 0.002 
Fair 3 1.75 (-7.24, 10.73) 0.703 97.3 <0.001 
Weak – – – – – 
Publication year of article ≤2010 3 1.75 (-7.24, 10.73) 0.703 97.3 <0.001 
>2010 6 − 0.98 (-3.81, 1.84) 0.495 74.4 0.002 
BMI: Body Mass Index, ng/mL: nanograms per milliliter, mg/d: milligram per day, g/d: gram per day, CI: confidence interval. 
Table 4 
Subgroup analyses for studies evaluating the effect of soy protein plus soy isoflavones on serum ICAM-1.   
Subgroup No. of trial Change in ICAM-1 (95 % CI) P-value I2 (%) Pheterogeneity 
Total – 12 2.68 (-0.98, 6.34) 0.151 67.6 <0.001 
Soy isoflavones dose ≤95 mg/d 6 3.38 (-2.06, 8.83) 0.223 70 0.005 
>95 mg/d 6 1.28 (-5.40, 7.95) 0.708 71 0.004 
Soy protein dose 
≤22 g/d 6 5.34 (0.48, 10.21) 0.031 58.5 0.034 
>22 g/d 6 0.15 (-5.84, 6.13) 0.961 74.8 0.001 
Design 
Parallel 4 9.0 (-11.92, 29.92) 0.399 66.5 0.030 
Cross-over 8 2.02 (-1.38, 5.41) 0.245 68.9 0.002 
intervention duration ≤56 day 10 3.12 (-0.50, 6.74) 0.910 70.2 <0.001 
>56 day 2 − 14.17 (-38.26, 9.91) 0.249 8.00 0.297 
Baseline ICAM ≤266 ng/mL 6 5.55 (-1.87, 12.96) 0.143 75.7 0.001 
>266 ng/mL 6 1.73 (-2.51, 5.97) 0.424 62.7 0.020 
Health status 
Healthy 3 7.42 (1.17, 13.68) 0.020 29.4 0.243 
At risk/disease 9 1.19 (-3.12, 5.51) 0.558 72 <0.001 
Sample size 
≤78 6 7.10 (-2.89, 17.09) 0.164 75 0.001 
>78 6 1.42 (-2.07, 4.91) 0.424 60.5 0.027 
Geographical Region 
Americas 5 3.83 (-4.20, 11.86) 0.350 72 0.007 
Europe 1 12 (4.53, 19.47) 0.002 – – 
Asia 6 1.73 (-2.51, 5.97) 0.424 62.7 0.02 
Sex 
Female 8 3.24 (-0.26, 6.75) 0.07 61.6 0.011 
Male – – – – – 
Both 4 5.69 (-6.63, 18.10) 0.365 77.7 0.004 
Age 
≤54.5 years 5 5.68 (5.90, 17.25) 0.336 70.6 0.009 
>54.5 year 5 0.46 (-7.39, 8.30) 0.909 76.6 0.002 
Unknown 2 4.00 (2.04, 5.96) <0.001 0 0.317 
BMI ≤27.2 6 6.19 (-0.32, 12.7) 0.063 59.5 0.03 
>27.2 6 0.22 (-4.63, 5.08) 0.928 74.9 0.001 
Quality assessment 
Good 6 2.61 (-8.49, 13.71) 0.645 69.1 0.006 
Fair 6 3.73 (-0.38, 7.08) 0.029 65.1 0.014 
Weak – – – – – 
Publication year of article 
≤2010 4 4.64 (2, 7.27) 0.001 44.7 0.143 
>2010 8 0.06 (-8.07, 8.19) 0.989 70.6 0.001 
ICAM-1: Intercellular Adhesion Molecule-1, BMI: Body Mass Index, ng/mL: nanograms per milliliter, mg/d: milligram per day, g/d: gram per day, CI: confidence 
interval. 
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effect size of soy protein combined with soy isoflavones. 
5. Conclusion 
According to the results of our meta-analysis, the combination of soy 
protein and soy isoflavones could not decrease the serum concentrations 
of E-selectin, ICAM-1, and VCAM-1. To confirm the results of the current 
study, we still need more RCTs with high quality, large sample size, 
longer intervention period, done on unhealthy participants, and in 
different parts of the world. Future studies should assess the effect of soy 
protein combined with soy isoflavones on equol and non-equol pro-
ducers separately and also measure the serum concentration of equol 
before and after the intervention. 
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